Nurten Ozen
Istanbul, 34116, Turkey (Türkiye)
NCT Number: NCT06844890
Depression is frequently seen among hemodialysis patients; however, it causes an impaired quality of life, a decrease in adherence to treatment, and an increase in hospitalization and mortality rate. It has been stated in the literature that the prevalence rate of depression in hemodialysis patients varies between 25-73%. Despite its high prevalence rate and adverse effects, it has been revealed that only a low rate of patients with depressive symptoms are diagnosed and treated. This is primarily associated with the fact that depressive symptoms in patients are not adequately recognized and examined.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Istanbul, 34116, Turkey (Türkiye)
Depression is assessed through structured clinical interviews or diagnostic scales. Structured clinical interviews are often regarded as the "gold standard" for the diagnosis of depressive disorders, since they are based on specific diagnostic criteria. However, since it is not always possible for patients to be evaluated by a psychiatrist, some scales are used instead. Even though these scales are not a diagnostic criterion, they are helpful in identifying patients at risk . However, screening may also result in false negatives, where cases of depression are not detected and, consequently, go untreated. Patients with kidney failure differ from the general population because they experience higher rates of comorbid depression. Indeed, there is a clear need for more effective screening tools for patients undergoing hemodialysis, given the wide variation in depression screening methods and the absence of a gold-standard assessment tool tailored to this specific population. Developing an easily administered, disease-specific self-report measure for depression could prove to be highly beneficial. There is only one study that has examined a depression tool specifically designed for patients on maintenance dialysis, known as the Depression Inventory-Maintenance Hemodialysis (DI-MHD)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 15 days
Depression Inventory for Maintenance Hemodialysis Patients The inventory, developed by the researchers consists of 17 items. In this four-point likert type scale; items are rated as never: 1 point, sometimes: 2 points, often: 3 points, and almost always: 4 points. Minimum and maximum scores of the inventory are 17 points and 68 points, respectively. Higher scores indicate that severity of fatigue increases. A score of 25 or more from the inventory indicates the presence of depression. At this cut-off point, the sensitivity and specificity of the inventory are 97% and 86%. The Cronbach's alpha value of the inventory is 0.893. The inventory has four subscales; low mood subscale: 7 items (7-28 points), inhibition of movement and thought subscale: 4 items (4-16 points), change in cognition subscale: 4 items (4-16 points), low self-evaluation subscale: 2 items (2-8 points). Higher scores mean that the situation reflected by the subscale worsens.
Istanbul University
Other
Depression Inventory for Maintenance Hemodialysis Patients: A Cross-Cultural Adaptation and Psychometric Evaluation in Turkey
Acronym: Depression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00505440
Behavior, Behavioral Symptoms
Columbus, Ohio, United States
View Trial DetailsNCT01624298
Behavior, Behavioral Symptoms
Lusaka, Zambia
View Trial DetailsNCT03157050
Anemia, Anemia, Hypochromic
View Trial DetailsNCT00186550
Behavior, Behavioral Symptoms
Stanford, California, United States
View Trial Details